Literature DB >> 8049236

Substrate-dependent mechanisms in the catalysis of human immunodeficiency virus protease.

L Polgár1, Z Szeltner, I Boros.   

Abstract

The most preferred residue in the substrates of human immunodeficiency virus (HIV-1) protease is glutamic acid in the P2' position. The catalytic importance of this charged residue has been studied to obtain a detailed insight into the mechanism of action, which will promote drug design to combat the virus. To this end, we have synthesized Lys-Ala-Arg-Val-Leu*Phe(NO2)-Glu-Ala-Nle (substrate E) and its counterpart containing the neutral Gln (substrate Q) in place of Glu. Kinetic analyses have shown that the specificity rate constants (kcat/Km) display bell-shaped pH dependencies for both substrates, but the pH-independent limiting value is 35-40-fold higher with substrate E than with substrate Q. In contrast to the pH-rate profiles of kcat/Km, there is a striking difference between the pH dependencies of Km and kcat for the two substrates. This indicates different ground state and transition state stabilizations in the two reactions. Solvent kinetic deuterium isotope effects show that the rate-limiting step for the hydrolysis of substrate E is a chemical step coupled with proton transfer whereas with substrate Q it is a physical step, presumably a conformational change. Accordingly, the charged residue in P2' alters the rate-limiting step and the nature of the enzyme-substrate complex, resulting in different mechanisms for the two substrates.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8049236     DOI: 10.1021/bi00197a040

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  14 in total

1.  Proteolytic cleavage of covalently linked cell wall proteins by Candida albicans Sap9 and Sap10.

Authors:  Lydia Schild; Antje Heyken; Piet W J de Groot; Ekkehard Hiller; Marlen Mock; Chris de Koster; Uwe Horn; Steffen Rupp; Bernhard Hube
Journal:  Eukaryot Cell       Date:  2010-11-19

2.  [Diagnosis and therapy of broncho-abdominal fistula following tuberculous cold abscess].

Authors:  G HEUER
Journal:  Arch Ohren Nasen Kehlkopfheilkd       Date:  1953

3.  Transition states of native and drug-resistant HIV-1 protease are the same.

Authors:  D Randal Kipp; Jennifer S Hirschi; Aya Wakata; Harris Goldstein; Vern L Schramm
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-09       Impact factor: 11.205

4.  Active-site mutations in the South african human immunodeficiency virus type 1 subtype C protease have a significant impact on clinical inhibitor binding: kinetic and thermodynamic study.

Authors:  Salerwe Mosebi; Lynn Morris; Heini W Dirr; Yasien Sayed
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

5.  Revealing the dimer dissociation and existence of a folded monomer of the mature HIV-2 protease.

Authors:  John M Louis; Rieko Ishima; Annie Aniana; Jane M Sayer
Journal:  Protein Sci       Date:  2009-12       Impact factor: 6.725

6.  Dynamic and Electrostatic Effects on the Reaction Catalyzed by HIV-1 Protease.

Authors:  Agnieszka Krzemińska; Vicent Moliner; Katarzyna Świderek
Journal:  J Am Chem Soc       Date:  2016-12-09       Impact factor: 15.419

7.  Trp42 rotamers report reduced flexibility when the inhibitor acetyl-pepstatin is bound to HIV-1 protease.

Authors:  B Ullrich; M Laberge; F Tölgyesi; Z Szeltner; L Polgár; J Fidy
Journal:  Protein Sci       Date:  2000-11       Impact factor: 6.725

Review 8.  Feline immunodeficiency virus (FIV) as a model for study of lentivirus infections: parallels with HIV.

Authors:  John H Elder; Ying-Chuan Lin; Elizabeth Fink; Chris K Grant
Journal:  Curr HIV Res       Date:  2010-01       Impact factor: 1.581

9.  Drug resistance in HIV-1 protease: Flexibility-assisted mechanism of compensatory mutations.

Authors:  Stefano Piana; Paolo Carloni; Ursula Rothlisberger
Journal:  Protein Sci       Date:  2002-10       Impact factor: 6.725

Review 10.  Molecular mechanisms of FIV infection.

Authors:  John H Elder; Magnus Sundstrom; Sohela de Rozieres; Aymeric de Parseval; Chris K Grant; Ying-Chuan Lin
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.